206 related articles for article (PubMed ID: 19596856)
1. Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo.
Khotskaya YB; Dai Y; Ritchie JP; MacLeod V; Yang Y; Zinn K; Sanderson RD
J Biol Chem; 2009 Sep; 284(38):26085-95. PubMed ID: 19596856
[TBL] [Abstract][Full Text] [Related]
2. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis.
Yang Y; Macleod V; Miao HQ; Theus A; Zhan F; Shaughnessy JD; Sawyer J; Li JP; Zcharia E; Vlodavsky I; Sanderson RD
J Biol Chem; 2007 May; 282(18):13326-33. PubMed ID: 17347152
[TBL] [Abstract][Full Text] [Related]
3. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
Yang Y; MacLeod V; Dai Y; Khotskaya-Sample Y; Shriver Z; Venkataraman G; Sasisekharan R; Naggi A; Torri G; Casu B; Vlodavsky I; Suva LJ; Epstein J; Yaccoby S; Shaughnessy JD; Barlogie B; Sanderson RD
Blood; 2007 Sep; 110(6):2041-8. PubMed ID: 17536013
[TBL] [Abstract][Full Text] [Related]
4. Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.
Purushothaman A; Toole BP
J Biol Chem; 2014 Feb; 289(9):5499-509. PubMed ID: 24403068
[TBL] [Abstract][Full Text] [Related]
5. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.
Ritchie JP; Ramani VC; Ren Y; Naggi A; Torri G; Casu B; Penco S; Pisano C; Carminati P; Tortoreto M; Zunino F; Vlodavsky I; Sanderson RD; Yang Y
Clin Cancer Res; 2011 Mar; 17(6):1382-93. PubMed ID: 21257720
[TBL] [Abstract][Full Text] [Related]
6. Soluble syndecan-1 promotes growth of myeloma tumors in vivo.
Yang Y; Yaccoby S; Liu W; Langford JK; Pumphrey CY; Theus A; Epstein J; Sanderson RD
Blood; 2002 Jul; 100(2):610-7. PubMed ID: 12091355
[TBL] [Abstract][Full Text] [Related]
7. Shed syndecan-1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: a novel mechanism of tumor-host cross-talk.
Stewart MD; Ramani VC; Sanderson RD
J Biol Chem; 2015 Jan; 290(2):941-9. PubMed ID: 25404732
[TBL] [Abstract][Full Text] [Related]
8. Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells.
Shimada K; Anai S; Fujii T; Tanaka N; Fujimoto K; Konishi N
J Pathol; 2013 Dec; 231(4):495-504. PubMed ID: 24549646
[TBL] [Abstract][Full Text] [Related]
9. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.
Purushothaman A; Uyama T; Kobayashi F; Yamada S; Sugahara K; Rapraeger AC; Sanderson RD
Blood; 2010 Mar; 115(12):2449-57. PubMed ID: 20097882
[TBL] [Abstract][Full Text] [Related]
10. High heparanase activity in multiple myeloma is associated with elevated microvessel density.
Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD
Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse.
Ramani VC; Sanderson RD
Matrix Biol; 2014 Apr; 35():215-22. PubMed ID: 24145151
[TBL] [Abstract][Full Text] [Related]
12. A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma.
Orecchia P; Conte R; Balza E; Petretto A; Mauri P; Mingari MC; Carnemolla B
Eur J Cancer; 2013 May; 49(8):2022-33. PubMed ID: 23352437
[TBL] [Abstract][Full Text] [Related]
13. RNAi-mediated knockdown of vascular endothelial growth factor inhibits vascularization and tumor growth in renal cell carcinoma.
Gu M; Zhang K; Yao HJ; Zhou J; Peng YB; Xu MX; Wang Z
Int J Mol Med; 2015 Oct; 36(4):1063-72. PubMed ID: 26310563
[TBL] [Abstract][Full Text] [Related]
14. Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells.
Lamorte S; Ferrero S; Aschero S; Monitillo L; Bussolati B; Omedè P; Ladetto M; Camussi G
Leukemia; 2012 May; 26(5):1081-90. PubMed ID: 22024722
[TBL] [Abstract][Full Text] [Related]
15. Melanocortin 1 receptor regulates melanoma cell migration by controlling syndecan-2 expression.
Chung H; Lee JH; Jeong D; Han IO; Oh ES
J Biol Chem; 2012 Jun; 287(23):19326-35. PubMed ID: 22493442
[TBL] [Abstract][Full Text] [Related]
16. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
[TBL] [Abstract][Full Text] [Related]
17. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.
Mahtouk K; Hose D; Raynaud P; Hundemer M; Jourdan M; Jourdan E; Pantesco V; Baudard M; De Vos J; Larroque M; Moehler T; Rossi JF; Rème T; Goldschmidt H; Klein B
Blood; 2007 Jun; 109(11):4914-23. PubMed ID: 17339423
[TBL] [Abstract][Full Text] [Related]
18. Syndecan-1 induction in lung microenvironment supports the establishment of breast tumor metastases.
Chute C; Yang X; Meyer K; Yang N; O'Neil K; Kasza I; Eliceiri K; Alexander C; Friedl A
Breast Cancer Res; 2018 Jul; 20(1):66. PubMed ID: 29976229
[TBL] [Abstract][Full Text] [Related]
19. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation.
Dhodapkar MV; Abe E; Theus A; Lacy M; Langford JK; Barlogie B; Sanderson RD
Blood; 1998 Apr; 91(8):2679-88. PubMed ID: 9531576
[TBL] [Abstract][Full Text] [Related]
20. Syndecan-1 overexpression promotes tumor growth and angiogenesis in an endometrial cancer xenograft model.
Oh JH; Lee HS; Park SH; Ryu HS; Min CK
Int J Gynecol Cancer; 2010 Jul; 20(5):751-6. PubMed ID: 20973264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
